All updated as on -
The CAGR for the projected period of 2023 to 2030 is 6.9%, with a growth rate of 20.2% expected for the global microscopic polyangiitis market size by 2032.
Microscopic polyangiitis (MPA), which is brought on by blood vessel inflammation, harms several organs, particularly the kidney, lungs, nerves, skin, and joints. Muscles may also be impacted by microscopic polyangiitis associated with myalgia, but these instances of necrotizing vasculitis being found in a muscle biopsy specimen are rare. Despite being an immune system-mediated condition, microscopic polyangiitis is not recognised to have a known aetiology. Numerous symptoms, including sickness, fever, weight loss, loss of appetite, bloody coughing in the case of the lungs, and loss of feeling in the case of the nerves, can be brought on by microscopic polyangiitis because it affects several organs. The diagnosis involves the use of imaging modalities such computed tomography (CT), magnetic resonance (MR) scans, and X-rays in addition to blood tests for red blood cells (RBCs) and antineutrophil cytoplasmic antibodies (ANCA). If the results of these tests are positive for the illness, microscopic polyangiitis can be diagnosed through biopsy (tissue sample testing).
Driving Factors
During the projection period, it is anticipated that key companies would introduce novel treatment alternatives, fueling global microscopic polyangiitis growth. For instance, in July 2018, the FDA granted InflaRx N.V. permission to conduct phase 2 clinical trials to assess the safety and effectiveness of IFX-1 for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, which is characterised by the presence of microscopic polyangiitis in the patient. InflaRx N.V. is a German biopharmaceutical company in the clinical stage. Additionally, the approval of novel medicines is expected to spur growth in the global market for microscopic polyangiitis throughout the projected time frame. Additionally, the government's enhanced funding and initiatives to increase public awareness of uncommon diseases and their impacts are projected to fuel the global market for microscopic polyangiitis. The market potential will expand during the anticipated period as a result of increasing R&D efforts and ongoing clinical trials for the treatment of microscopic polyangiitis.
Restraining Factors
Since microscopic polyangiitis is an uncommon condition with an unknown aetiology, it can be challenging to diagnose and its symptoms might be mistaken for those of many other illnesses. As a result, the market's expansion would be constrained. Corticosteroids' negative side effects, such as skin thinning and agonising agony, restrain market expansion. Additionally, azathioprine may result in side effects like diarrhoea, pain in the joints, lack of coordination, seizures, and changed vision. Over the anticipated period, these factors are estimated to restrain the expansion of the microscopic polyangiitis market globally. The high cost of drugs and lack of approved treatments and therapies would hinder and challenge the global market for microscopic polyangiitis over the forecast period.
Report Coverage
Global Microscopic Polyangiitis (MPA) research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Microscopic Polyangiitis (MPA) report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Microscopic Polyangiitis (MPA) competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Microscopic Polyangiitis (MPA) market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Microscopic Polyangiitis (MPA) market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Microscopic Polyangiitis (MPA) market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Genentech, Inc., Celltrion, Inc., InflaRx N.V., ChemoCentryx Inc., Bristol-Myers Squibb Company, Teijin Pharma Ltd, Amerigen Pharmaceuticals Limited, Sandoz International GmbH, TTY Biopharm Company Ltd
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Microscopic Polyangiitis (MPA) market based on the below-mentioned segments:
Global Microscopic Polyangiitis (MPA) Market, By Drug
Global Microscopic Polyangiitis (MPA) market, By Distribution Channel
Global Microscopic Polyangiitis (MPA) market, Regional Analysis
Microscopic polyangiitis (MPA), which is brought on by blood vessel inflammation, harms several organs, particularly the kidney, lungs, nerves, skin, and joints. Muscles may also be impacted by microscopic polyangiitis associated with myalgia, but these instances of necrotizing vasculitis being found in a muscle biopsy specimen are rare. Despite being an immune system-mediated condition, microscopic polyangiitis is not recognised to have a known aetiology. Numerous symptoms, including sickness, fever, weight loss, loss of appetite, bloody coughing in the case of the lungs, and loss of feeling in the case of the nerves, can be brought on by microscopic polyangiitis because it affects several organs. The diagnosis involves the use of imaging modalities such computed tomography (CT), magnetic resonance (MR) scans, and X-rays in addition to blood tests for red blood cells (RBCs) and antineutrophil cytoplasmic antibodies (ANCA). If the results of these tests are positive for the illness, microscopic polyangiitis can be diagnosed through biopsy (tissue sample testing).
Driving Factors
During the projection period, it is anticipated that key companies would introduce novel treatment alternatives, fueling global microscopic polyangiitis growth. For instance, in July 2018, the FDA granted InflaRx N.V. permission to conduct phase 2 clinical trials to assess the safety and effectiveness of IFX-1 for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, which is characterised by the presence of microscopic polyangiitis in the patient. InflaRx N.V. is a German biopharmaceutical company in the clinical stage. Additionally, the approval of novel medicines is expected to spur growth in the global market for microscopic polyangiitis throughout the projected time frame. Additionally, the government's enhanced funding and initiatives to increase public awareness of uncommon diseases and their impacts are projected to fuel the global market for microscopic polyangiitis. The market potential will expand during the anticipated period as a result of increasing R&D efforts and ongoing clinical trials for the treatment of microscopic polyangiitis.
Restraining Factors
Since microscopic polyangiitis is an uncommon condition with an unknown aetiology, it can be challenging to diagnose and its symptoms might be mistaken for those of many other illnesses. As a result, the market's expansion would be constrained. Corticosteroids' negative side effects, such as skin thinning and agonising agony, restrain market expansion. Additionally, azathioprine may result in side effects like diarrhoea, pain in the joints, lack of coordination, seizures, and changed vision. Over the anticipated period, these factors are estimated to restrain the expansion of the microscopic polyangiitis market globally. The high cost of drugs and lack of approved treatments and therapies would hinder and challenge the global market for microscopic polyangiitis over the forecast period.
Report Coverage
Global Microscopic Polyangiitis (MPA) research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Microscopic Polyangiitis (MPA) report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Microscopic Polyangiitis (MPA) competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Microscopic Polyangiitis (MPA) market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Genentech, Inc., Celltrion, Inc., InflaRx N.V., ChemoCentryx Inc., Bristol-Myers Squibb Company, Teijin Pharma Ltd, Amerigen Pharmaceuticals Limited, Sandoz International GmbH, TTY Biopharm Company Ltd |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Microscopic Polyangiitis (MPA) Market from 2021 to 2030.
- Market Forecast for Microscopic Polyangiitis (MPA) Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Microscopic Polyangiitis (MPA) competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Microscopic Polyangiitis (MPA)
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Microscopic Polyangiitis (MPA) market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Microscopic Polyangiitis (MPA) market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Genentech, Inc., Celltrion, Inc., InflaRx N.V., ChemoCentryx Inc., Bristol-Myers Squibb Company, Teijin Pharma Ltd, Amerigen Pharmaceuticals Limited, Sandoz International GmbH, TTY Biopharm Company Ltd
Primary Target Market
- Market Players of Microscopic Polyangiitis (MPA)
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Microscopic Polyangiitis (MPA) market based on the below-mentioned segments:
Global Microscopic Polyangiitis (MPA) Market, By Drug
- Rituximab
- Azathioprine
- Cyclophosphamide
- Prednisone
- Pipeline Drugs
- Others
Global Microscopic Polyangiitis (MPA) market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Microscopic Polyangiitis (MPA) market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive microscopic polyangiitis mpa market market research and competitor analysis for your business to help you develop more profound insights into the microscopic polyangiitis mpa market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the microscopic polyangiitis mpa market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.